The escalating burden of blood cancer presents a pressing global health concern, with its incidence rising steadily. This surge is attributed to various factors, including an aging population, lifestyle changes, and environmental influences. However, amidst this challenge, advancements in Blood Cancer Diagnostics D...
Find MoreDate of Abstract presentation12th December 2023IndicationsMantle Cell Lymphoma (MCL)Abstract NumberLBA-2Abstract typeOral Ibrutinib, an oral BTK inhibitor, holds approval in numerous countries for the treatment of R/R MCL. Similarly, venetoclax, an oral BCL2 inhibitor, has gained approval in multiple countries f...
Find MoreDate of Abstract presentation11th December 2023IndicationsRelapsed or Refractory (R/R) B-Cell MalignanciesAbstract Number4401Abstract typePoster The preliminary results from this ongoing clinical trial, unveiled at the ASH 2023 conference, demonstrated that, among the efficacy evaluable patients (n=28), BGB-1667...
Find MoreDate of Abstract presentation11th December 2023IndicationsMultiple MyelomaAbstract Number1014Abstract typeOral TALVEY (talquetamab) is a bispecific T-cell engaging antibody designed to target the CD3 receptor found on T-cells and G protein-coupled receptor class C group 5 member D (GPRC5D). The findings presente...
Find MoreDate of Abstract presentation12th December 2023IndicationsAcute LeukemiaAbstract NumberLBA-5Abstract typePoster According to the data presented at the ASH 2023 conference, as of the July 2023 data cutoff, the pivotal trial AUGMENT-101 included 94 patients with acute leukemia within the KMT2Ar cohorts. Among them...
Find MoreThe upcoming 65th American Society of Hematology (ASH) Annual Meeting and Exposition 2023 is just around the corner, and leading pharmaceutical giants like BMS, Genmab, AstraZeneca, Regeneron, BeiGene, ADC Therapeutics, Eli Lilly and Company, Janssen, and others are gearing up for this conference. This conference w...
Find MoreMeasurable or Minimal Residual Disease (MRD) is a term often used when treating patients with blood cancers. MRD is a small number of cancer cells left in the body after cancer treatment, and these cells can potentially cause relapse in these patients. The number of remaining cells is often too small to cause any s...
Find MoreDaiichi Sankyo Receives the First Approval for its Blood Cancer Drug Ezharmia Daiichi Sankyo has received the first global approval for Ezharmia, a first-in-class dual EZH1 and EZH2 inhibitor for the treatment of patients with relapsed or refractory adult T-cell leukemia/lymphoma (ATL). The Japanese Ministry of ...
Find MoreJohnson & Johnson nabs another combo approval for myeloma star Darzalex Late last year, Johnson & Johnson widened Darzalex’s reach with some combo approvals. And now, it’s adding to that roster. The medication has snagged a green light for use in tandem with chemo drug dexamethasone and Celgene’s Pomalyst fo...
Find MoreThe American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.